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Dear Editor;
Venous Thromboembolism (VTE) is the 3rd most preva-
lent vascular disease behind myocardial infarction and cere-
brovascular ischemic attack (1). This disorder has received
attention from health policy makers because of its major
complications including recurrent VTE, post thrombotic syn-
drome, sudden cardiac death and high mortality rate (2). In
the United States, VTE was reported in approximately 201000
cases annually, 25% of which expired within 7 days after di-
agnosis and 22% of mortalities did not have a definitive diag-
nosis. Despite the progression in diagnosis and treatment of
VTE since 1979, its incidence did not decrease dramatically.
This gap declares that VTE risk factors, especially transient
ones, have not been detected completely (3).
Obesity, history of VTE, family history of VTE, recent surgery,
malignancy, myeloproliferative disorders, trauma, preg-
nancy, post-menopausal hormone therapy, hereditary syn-
dromes like anti phospholipid syndrome (APS), chronic kid-
ney disease (CKD), chronic obstructive pulmonary disease
(COPD), blood transfusion and older age are determined as
major risk factors. These factors can be categorized into two
major subgroups as intrinsic and predisposing. Recent in-
vestigations focused on predisposing ones, which can be jus-
tified (2, 4).
Designing a cross sectional study in Imam Hossein Hospital,
Tehran, Iran, from 2016 to 2017, we found that inactivity due
to disability (30.9%), smoking (29.3%), and active malignancy
(18.1%), were the most prevalent transient risks factor of VTE
in our sample, respectively. Similar to our results, Kesieme
et al. (5) and Cushman et al. (2) declared that VTE is more
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diagnosed in the elderly. Park MS et al. (3) introduced re-
cent surgery, trauma (73%), and disability to walk (62%) as
major independent risk factors of VTE. Fuji T et al. (6) intro-
duced malignancy, recent infectious disease, and obesity as
the factors predisposing patients who were admitted for or-
thopedic surgery to VTE. As can be seen, despite the risk fac-
tors of VTE being the same in various studies, their frequency
varied between the studies. Population and cultural charac-
teristics and various habits may have an effect in this regard.
Therefore, it is suggested to perform a multi-center, compre-
hensive study considering all the racial and ethnic in order to
have a correct pattern of the frequency of predisposing fac-
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